Protocol Ledger

NCT03472560 · Phase II · TERMINATED

A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)

Interventional Phase II clinical trial protocol NCT03472560 sponsored by Pfizer in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-05-02 Enrollment: 61 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03472560
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)61 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03472560
Protocol FieldVerified Registry Value
NCT IdentifierNCT03472560
Consolidated Lead SponsorPfizer
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment61 participants (ACTUAL)
Registered Start Date2018-05-02
WhyStopped ClassificationSafety / Toxicity / Adverse Events

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI